Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 121.59 -1.05 (-0.86%) Market Cap: 7.35 Bil Enterprise Value: 10.93 Bil PE Ratio: 17.13 PB Ratio: 1.76 GF Score: 85/100

Jazz Pharmaceuticals PLC at RBC Capital Markets Healthcare Conference Transcript

May 21, 2019 / 01:00PM GMT
Release Date Price: $139.91 (+1.14%)
Randall S. Stanicky
RBC Capital Markets, LLC, Research Division - MD of Global Equity Research and Lead Analyst

My name is Randall Stanicky, I come from the Specialty Pharmaceuticals Sectors here at RBC Capital Markets. I'm pleased to have our next presentation. We have Matt Young, the Chief Financial Officer; and Mike Miller, who heads up Commercial for Jazz Pharmaceuticals.

Questions & Answers

Randall S. Stanicky
RBC Capital Markets, LLC, Research Division - MD of Global Equity Research and Lead Analyst

You guys have a lot going on, Sunosi just approved, JZP-258 data out and a lot to talk about here. But I want to throw out a bigger picture question that probably kicks off maybe a larger discussion. And Matt, I think you probably know where I'm going maybe with this. There's been a lot of focus on Vyxeos the move to HemOnc, growing out that platform, the need to diversify away from Xyrem. I think most can step back and say, we'd hoped Vyxeos might have wrapped a bit quicker. And so let me just throw this question to, you to begin with, do we need

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot